Fundraising Fox
Pasithea Therapeutics
NASDAQ: KTTAVenice, US · Founded 2020 · Delaware corporation · 2 known investors
Find your way into Pasithea Therapeutics
Sign up to see every warm intro you have to Pasithea Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pasithea Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.
Founders & leadership
Pasithea Therapeutics was founded in 2020 by Lawrence Steinman and Tiago Reis Marques.
LS
Lawrence SteinmanCo-founder
TR
Tiago Reis MarquesCo-founder · Chief Executive OfficerTiago Reis Marques is a psychiatrist and neuroscience researcher with over 15 years of experience in psychiatric disorders, serving as CEO of Pasithea Therapeutics; he holds positions as a senior fellow at Imperial College London and clinical lecturer at King's College London's Institute of Psychiatry, Psychology & Neuroscience, and has conducted research using PET and MRI imaging to identify neurobiological treatment targets for mental illness.
IM
Israel Maxx AbramowitzNamed on SEC filing
CA
Craig AuringerNamed on SEC filing
Investors · 2
Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M
How we know: Vivo Capital's portfolio page · funding news · Not right? Tell us
Janus Henderson InvestorsreportedLondon
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$31.8M disclosed across 3 of 4 rounds · 2020–2025
▶$30.4MraisedDec 2021 · 21 investors · BiotechnologyRule 506(b)
▶$30.4MraisedDec 2021 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence SteinmanDirector
- Simon DumesnilDirector
- Stanley M. GlossExecutive Officer
- Emer LeahyDirector
- Tiago Andre Dos Reis MarquesExecutive Officer, Director
- Yassine BendiabdallahExecutive Officer, Director
- Offering amount
- $30.4M
- Amount sold
- $30.4M
- Sales commissions
- $2.7M
- Placement agents
- EF Hutton, division of Benchmark Investments, LLC
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.2MraisedMar 2021 · 30 investors · Other Health CareRule 506(b)
▶$1.2MraisedMar 2021 · 30 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence SteinmanDirector
- Tiago Reis MarquesDirector
- Israel Maxx AbramowitzExecutive Officer, Director
- Craig AuringerExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$250KraisedJan 2021 · 1 investors · Other Health CareRule 506(b)
▶$250KraisedJan 2021 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence SteinmanDirector
- Tiago Reis MarquesDirector
- Israel Maxx AbramowitzExecutive Officer, Director
- Craig AuringerExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $250K
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$65.3Mvaluation at IPOSep 2021 · $5.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 5
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Pasithea Therapeutics.
In the news
Frequently asked questions
- What does Pasithea Therapeutics do?
- Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.
- Who founded Pasithea Therapeutics?
- Pasithea Therapeutics was founded by Lawrence Steinman, Tiago Reis Marques in 2020.
- Who are Pasithea Therapeutics's investors?
- Pasithea Therapeutics's investors include Vivo Capital, Janus Henderson Investors.
- How much funding has Pasithea Therapeutics raised?
- Pasithea Therapeutics has disclosed $31.8M raised across 3 of its 4 known rounds.
- Where is Pasithea Therapeutics headquartered?
- Pasithea Therapeutics is headquartered in Venice, US.